A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and lipid absorption and metabolism and body composition, in comparision with Xenical.
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Acarbose/orlistat (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Empros Pharma
- 11 May 2017 Status changed from recruiting to completed.
- 13 Sep 2016 New trial record